Safety and Efficiency of Intravenous Push Lacosamide Administration
- 11.06.2018
- Original Article
Erschienen in:
- Verfasst von
- K. Erin Davidson
- Joshua Newell
- Khalid Alsherbini
- Joseph Krushinski
- G. Morgan Jones
- Erschienen in
- Neurocritical Care | Ausgabe 3/2018
Abstract
Background/objective
Intravenous (IV) lacosamide use for status epilepticus has increased in recent years and is recommended for refractory status epilepticus by current guidelines. Per the lacosamide package labeling, the preferred route of administration is diluted and infused over 30–60 min; however, administration undiluted is also acceptable and recent literature demonstrated safety at a maximum rate of 80 mg per minute (Kellinghaus et al. in Acta Neurol Scand 123:137–141, 2011). Undiluted administration as an IV push has potential to increase efficiency of administration to patients needing urgent seizure control since it may be dispensed from automatic dispensing cabinets in patient care areas. This study aims to compare safety outcomes and efficiency of administration in patients receiving lacosamide IV push compared to IV piggyback.
Methods
We present a single-center, retrospective cohort study of patients receiving lacosamide via IV piggyback or IV push from June 2016 to July 2017. Baseline characteristics, data related to potential safety concerns and timing of ordering, verification, and administration were collected. The primary safety outcomes were incidence of infusion site reactions, hypotension (systolic blood pressure [SBP] < 90 mm Hg), and bradycardia (heart rate [HR] < 50 beats per minute) documented within 2 h of each lacosamide dose. Secondary safety outcomes included the incidence of PR interval prolongation in patients with at least one electrocardiogram measured. The primary efficiency outcome was the time between order verification and administration.
Results
Patients in the IV piggyback (n = 88) and IV push (n = 78) groups had similar baseline characteristics, initial dose, SBP, and HR. Hypotension (8 vs. 10.3%) and bradycardia (2.3 vs. 2.6%) rates were similar among both groups (p > 0.05). Only one patient in each group had documented PR prolongation, and no documented infusion reactions occurred. Median time from order verification to administration was significantly reduced in the IV push group (35 min vs. 1 h 49 min; p < 0.001).
Conclusions
Administration of lacosamide via IV push results in similar adverse effect rates to IV piggyback preparations with more efficient time to administration.
Anzeige
- Titel
- Safety and Efficiency of Intravenous Push Lacosamide Administration
- Verfasst von
-
K. Erin Davidson
Joshua Newell
Khalid Alsherbini
Joseph Krushinski
G. Morgan Jones
- Publikationsdatum
- 11.06.2018
- Verlag
- Springer US
- Erschienen in
-
Neurocritical Care / Ausgabe 3/2018
Print ISSN: 1541-6933
Elektronische ISSN: 1556-0961 - DOI
- https://doi.org/10.1007/s12028-018-0560-6
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
